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a b s t r a c t
Background and purpose: To examine the risk of cardiac conduction abnormalities or severe ventricular
arrhythmias requiring implantation of a cardiac implantable electronic device (CIED), either a pacemaker
or an implantable cardioverter-defibrillator, subsequent to breast cancer (BC) radiotherapy (RT).
Material and methods: All women treated for early-stage BC in Denmark from 1982 to 2005 were iden-
tified from the Danish Breast Cancer Cooperative Group. By record linkage to the Danish Pacemaker
and ICD Registry information was retrieved on CIED implants subsequent to RT. Standardized incidence
ratios (SIR) of CIED implantation were estimated for women receiving RT and compared to women not
receiving RT for BC. Uni- and multivariate Poisson regression models were used to estimate incidence rate
ratios (IRR) among irradiated women compared to non-irradiated.
Results: Of 44,423 BC patients, 179 had a CIED implanted among 18,251 women who received RT, and
401 had a CIED in 26,172 who did not receive RT. The unadjusted IRR was 1.09 (0.91–1.30 95% CI) for
CIED implants among women receiving RT compared to non-irradiated women and the IRR was 1.13
(0.93–1.38 95% CI) when adjustments were made.
Conclusions: BC RT as practiced in Denmark in 1982–2005 did not increase the risk of CIED implants. This
indicates that RT for BC does not increase the risk of severe ventricular arrhythmias or cardiac conduction
abnormalities.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 122 (2017) 60–65 This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Breast cancer (BC) after non-melanoma skin cancer is the most
frequent malignant disease among women in Denmark as well as
in the world [1]. Treatment modalities for early stage BC include
surgery, radiotherapy (RT), and systemic medical treatment.
The benefits of postoperative RT in early stage BC have been
documented in randomized clinical trials and include moderate
reductions in BC mortality and substantial reductions in local
recurrence, resulting in considerable improvements in BC survival
[2–4].
However, one of the main concerns regarding RT is the radiation
dose to the heart. Data from Denmark and Sweden suggest a linear
relationship between an increasing risk of ischemic heart disease
and an increasing dose to the heart [5]. Though doses to the heart
have been reduced in modern RT regimens, the mean heart dose is
around 3.3 Gy for right-sided and 5.4 Gy for left-sided BC but with
a wide variation between regimens and countries [6].
The first report of electrocardiogram (ECG) changes after medi-
astinal radiation was published in 1925 [7]. Since then, ECG
changes have been documented after mediastinal RT for Hodgkin’s
lymphoma (HL) [8–14]. Evidence is more sparse after RT for BC. A
study of 69 Swedish BC patients comparing ECG before and after RT
showed that there was a high incidence of T-wave changes
6 months after RT for left-sided BC but the ECG changes were
reversible. The perimyocardial damage was functionally insignifi-
cant at long-term follow-up [15].
ECG changes constitute a quite heterogeneous pattern. They
range from transient and harmless (single supra ventricular pre-
mature complexes, T-wave inversion) without a need for treat-
ment, to severe and life-threatening (high degree AV-block, sinus
node dysfunction and ventricular tachyarrhythmias) with an indi-
cation for either a pacemaker or an implantable cardioverter defib-
rillator [16]. The aim of this study was to examine if BC RT was
associated with a risk of so severe arrhythmias and conduction
abnormalities that implantation of a cardiovascular implantable
electronic device (CIED), was needed.
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Methods
Study design and subject selection
This is a register based cohort study. Data were ascertained
through three Danish national registries; The Danish Breast Cancer
Cooperative Group Registry (DBCG), The Danish Pacemaker and
ICD Registry (DPIR), and the Danish National Patient Register (LPR).
DBCG has registered all women with primary, early-stage BC in
Denmark since 1977. More than 80,000 women are registered and
the registry has been validated to have close to complete ascertain-
ment [17]. The DBCG registry includes individual patient informa-
tion on demographic and histopathological variables, treatment
modalities (surgery, medical treatment and RT) and follow-up for
recurrence and death. All Danish hospitals involved in diagnosis
and treatment of BC patients (breast surgeons, pathologists and
oncologists) are reporting to this registry.
We identified 64,071 women diagnosed with histologically ver-
ified, early-stage (stage I-IIIC/non-metastatic) BC in Denmark from
1st January 1982 to 31st December 2005 and without prior malig-
nancies (Fig. 1). A total of 2099 women were excluded since they
only had a breast biopsy, 1311 patients because of bilateral BC,
2024 women due to unknown BC laterality, 2768 patients because
of old age (more than 80 years at the time of the diagnosis) and 322
with a follow-up of less than 6 months. Additionally, 8492 patients
were excluded due to lack of valid information on RT. Patients were
selected for RT according to the guidelines from the DBCG [18]. RT
was not recommended as a standard treatment for patients over
the age of 70 years after a mastectomy but for all patients after
breast conserving surgery. From 1982 to 1989, there were three
regimens after mastectomy, 50 Gy in 25 fractions over 5 weeks,
48 Gy in 24 fractions over 5 weeks, and 36 Gy in 20 fractions over
4 weeks, the latter with orthovoltage. After breast conserving sur-
gery 50 Gy was given in 25 fractions over 5 weeks some with an
additional boost of 10–24 Gy. From 1989 to 2005 after breast con-
serving surgery, all patients were given 48 Gy in 24 fractions over
4.5 weeks with boost doses of 10–16 Gy in 5–8 fractions to the
tumor bed. Endocrine therapy included tamoxifen only, initially
for 1–2 years, later for 5 years, from 1977 to 2007 [17].
DPIR started in 1982 and has registered all CIEDs including per-
manent pacemakers (PMs), implantable cardioverter defibrillators
(ICDs) and cardiac resynchronization therapy devices with defibril-
lators (CRT-Ds) or without (CRT-Ps). More than 30,000 Danish
women are registered in the DPIR, which includes individual
patient information of new implants, re-implants, indication for
the implant, and clinical symptoms of the patient [19].
The Danish personal identification number enabled a linkage
between DBCG and DPIR. Hereby, information on CIED among
women treated with radiation for BC were retrieved [20]. We iden-
tified 210 patients with a CIED implanted prior to the BC diagnosis
and 20 patients who had a CIED implanted within 6 months post
diagnosis. These were excluded.
LPR was established in 1977, and the register has been
expanded over the years, from originally covering only somatic
inpatients to covering somatic as well as psychiatric in- and out-
patients in all hospitals in Denmark today. The registry has been
maintained by a public enterprise under the Danish Ministry of
Health [21]. Information about prior cardiac disease was identified
from the LPR and was defined as having any of the following ICD-
codes at least 30 days before the BC diagnosis; conduction abnor-
mality/arrhythmia, ICD8 427.90–427.98/ICD10 I44, 45, I47-49,
other cardiac diseases, ICD8 390.00–429.99/ICD10 I00-I52 (ICD-
codes for conduction abnormality/arrhythmia not included).
The Danish Health and Medicines Authority and the Danish
Data Protection Agency approved the study.
Statistical methods
Differences in patient characteristics between BC patients who
had received RT and BC patients who had not received RT were
tested using the v2-test. Level of significance was set to 5%. Crude
standardized incidence ratios (SIR) were estimated for CIED
implants as the observed numbers of CIED implants divided by
the expected number of CIED implants. The expected number of
implants was estimated from accumulated person-year at risk
and CIED implant rates of the general Danish female population
in five-year calendar-time and age groups. Ninety-five percent con-
fidence intervals (CI) were formed assuming the expected numbers
to be Poisson-distributed. Time at risk started 6 months after BC
diagnosis, to avoid inclusion of CIED implants during RT for
arrhythmias and conduction abnormalities prevalent prior to RT.
Time at risk ended at death, emigration, CIED implant or at last
date of follow-up (1st July 2014), whichever occurred first. Poisson
regression models were applied to assess the incidence rate ratio
(IRR) and standard likelihood ratio tests comparing Poisson’s
regression models were used to test for heterogeneity across sub-
groups. Univariate analysis of the parameters included follow-up
time. The multivariate model further included RT, calendar year
of diagnosis, age at diagnosis, time since diagnosis, axillary lymph
nodal status, estrogen receptor status, laterality of BC, adjuvant
medical treatment and prior cardiac disease.
The calendar years of BC diagnosis were divided into three
groups according to different treatment strategies. The first group
covers the period 1982–1989, when anthracyclines were not used
in standard chemotherapy. The second group covers the period
1990–2002. As anthracyclines were used in a trial study by the
end of 1989, and became standard as of 1999 onward. The third
group covers the period 2003–2005, when it was decided that
the internal mammary nodes should be irradiated only for women
with right-sided BC, in order to reduce the radiation dose to the
heart for left-sided BC.
Analyses were made with STATA 14 [22].
Patients recorded in the 
DBCG1 database 1982-2005 
N=64071
N=63841
Patients included in  
the study cohort 
N=44423
210 Patients treated with a CIED2
prior to breast cancer 
20 Patients treated with a CIED  
prior to radiotherapy
2099 Patients with no surgery 
1311 Patients with bilateral breast cancer 
2024 Patients with unknown  
breast cancer laterality  
2402 Patients with unknown  
radiotherapy status
8492 Patients with radiotherapy status 
indicated, but not reported
2768 Patients aged 80 at breast  
cancer diagnosis
322 Patients with <6  month follow-up 
Fig. 1. Inclusion and exclusion flowchart. 1The Danish Breast Cancer Cooperative
Group. 2Cardiovascular Implantable Electronic Device.
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Results
After the exclusions the final study population included 44,423
patients with early-stage BC (Fig. 1). The median age at BC diagno-
sis was 57 years (range 21–79). Median follow-up time was
11.7 years (interquartile range, 6.1–16.3) with 30% having more
than 15 years of follow-up. Table 1 shows that the use of RT
increased with calendar time from 26% of patients diagnosed in
1982–1989 to 74% of patients diagnosed in 2003–2005 (p < 0.01).
RT was more frequent in younger patients, among axillary lymph
node positive patients and among patients receiving chemother-
apy with anthracyclines (p < 0.01 for all). Chemotherapy with
anthracyclines was used in 20% of patients receiving RT compared
to 4% in non-irradiated patients. Prior cardiac disease was equally
present in patients with and without RT (7% and 8%, respectively).
Among the 18,251 women receiving RT, 179 (1.0%) had a CIED
implanted subsequent to RT compared to 401 (1.5%) among the
26,172 women who did not receive RT (Table 1). Table 2 shows
the distribution of the 580 implanted CIEDs distributed according
to indication. The majority (91%) of the CIEDs was PMs. The indica-
tions, irrespective of device, were sinus node dysfunction (N = 266,
46%), AV block (N = 206, 36%), and ventricular tachyarrhythmias
(N = 30, 5%). Fig. 2 illustrates the location of the sinoatrial (SA)
and atrioventricular (AV) nodes in relation to tangential RT for a
left-sided BC.
The study cohort accrued close to half a million person-years
(521,574) in whom 573.2 CIED were expected compared with
580 observed, yielding a crude SIR of 1.01 (95% CI 0.93–1.10)
(Table 3). In the univariate analysis, there was a statistically signif-
icant increase in CIED implants with an increase in years since BC
diagnosis (p = 0.02) and a presence of prior cardiac disease
(p < 0.01), and also a statistically significant decrease in CIED
implants among estrogen receptor negative patients (p = 0.02).
The multivariate analysis did not reveal statistically significant
associations with RT. There was a reduced risk of CIED implants
among patients with negative axillary lymph mode status
(p = 0.01) and negative estrogen receptor status (p < 0.01). Notably,
chemotherapy with anthracyclines did not increase the risk of hav-
ing a CIED. In the multivariate model, there were no statistically
significant interactions between RT and; time since diagnosis,
age at BC diagnosis, axillary lymph node status, laterality of BC
or prior cardiac disease.
Among 18,251 women treated with radiation, 9282 had
left-sided and 8969 right-sided BC. IRR for implants of CIED
Table 1
Characteristics of the 44,423 women in the study population by radiotherapy status and number of Cardiovascular Implantable Electronic Devices.
Numbers of patients Numbers of CIEDa
RT (%)b No RT(%)b Total RT (%)c No RT (%)d Total
Year of breast cancer diagnosis
1982–1989 2520 (26) 7330 (74) 9850 33 (1.3) 138 (1.9) 171
1990–2002 10,229 (38) 16,864 (62) 27,093 115 (1.1) 249 (1.5) 364
2003–2005 5502 (74) 1978 (26) 7480 31 (0.6) 14 (0.7) 45
Age at breast cancer diagnosis (yrs)
<50 6406 (52) 5887 (48) 12,293 21 (0.3) 37 (0.6) 58
50–59 5980 (45) 7231 (55) 13,211 59 (1.0) 74 (1.0) 133
60–69 4709 (38) 7832 (62) 12,541 70 (1.5) 171 (2.2) 241
70–79 1156 (18) 5222 (82) 6378 29 (2.5) 119 (2.3) 148
Axillary lymph node status
Positive 11194 (57) 8606 (43) 19800 100 (0.9) 106 (1.2) 206
Negative 7002 (29) 17046 (71) 24048 78 (1.1) 284 (1.7) 362
Unknown 55 (10) 520 (90) 575 1 (1.8) 11 (2.1) 12
Estrogen receptor status
Positive (P10%) 12674 (45) 15277 (55) 27951 129 (1.0) 248 (1.6) 377
Negative (0–9%) 3656 (42) 5007 (58) 8663 19 (0.5) 43 (0.9) 62
Unknown 1921 (25) 5888 (75) 7809 31 (1.6) 110 (1.9) 141
Laterality of breast cancer
Left 9282 (41) 13485 (59) 22767 90 (1.0) 211 (1.6) 301
Right 8969 (41) 12687 (59) 21656 89 (1.0) 190 (1.5) 279
Adjuvant medical treatment
Anthracyclines 3564 (76) 1132 (24) 4696 14 (0.4) 0 (0.0) 14
Other chemotherapy 3191 (49) 3369 (51) 6560 16 (0.5) 27 (0.8) 43
Endocrine therapye (alone) 5877 (53) 5280 (47) 11,157 76 (1.3) 77 (1.5) 153
None 4639 (28) 12220 (72) 16859 65 (1.4) 231 (1.9) 296
Unknown/indicated but not reported 980 (19) 4171 (81) 5151 8 (0.8) 66 (1.6) 74
Prior cardiac diseasef
Conduction disorders & arrhythmiasg 341 (37) 571 (63) 912 13 (3.8) 30 (5.3) 43
Other cardiac diseasesh 932 (36) 1653 (64) 2585 20 (2.1) 49 (3.0) 69
No/Unknown 16,978 (41) 23,948 (59) 40,926 146 (0.9) 322 (1.3) 468
All women 18,251 (41) 26,172 (59) 44,423 179 (1.0) 401 (1.5) 580
a Cardiovascular implantable electronic device.
b Row percentages.
c Percentages of implants among irradiated women.
d Percentages of implants among non-irradiated women.
e Endocrine therapy included tamoxifen only, initially for 1–2 years, later for 5 years, from 1977 to 2007. Since 2007 aromatase inhibitors for 5 years were recommended to
postmenopausal women while premenopausal women continued to receive tamoxifen for 5 years [17].
f Defined as having any of the following ICD-codes at least 30 days before cancer diagnosis.
g ICD10 I44 (atrioventricular block & left bundle-branch block), I45 (right bundle-branch block, sinus arrest, conduction disorder unspecified), I47–49 (supra ventricular &
ventricular tachycardia, atrial fibrillation/flutter, ventricular fibrillation/flutter, sick sinus syndrome) & ICD8 427.90–427.98 (corresponding to ICD10-codes).
h ICD10 I00-I52 (acute rheumatic fever, chronic rheumatic heart diseases, hypertensive diseases, ischemic heart diseases, pulmonary heart disease and diseases of
pulmonary circulation, other forms of heart disease) & ICD8 390.00–429.99 (corresponding to ICD10-codes) (ICD-codes for conduction abnormality/arrhythmia not included).
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comparing left- with right-sided RT was 0.96 (95% CI 0.72–1.29,
p = 0.78), and this estimate remained virtually the same
(0.97, 95% CI 0.72–1.30, p = 0.84) after adjustment for calendar year
of diagnosis, age at diagnosis, time since diagnosis, axillary lymph
node status, estrogen receptor status, adjuvant medical treatment
and prior cardiac disease.
Discussion
Based on more than 40,000 patients with early-stage BC fol-
lowed for up to 32 years, this nationwide registry-based cohort
study failed to detect a statistically significant association between
incidence of implantation of a CIED and RT. This suggests that BC
RT does not seem to increase the risk of so severe cardiac arrhyth-
mias or conductions abnormalities that implantation of a CIED is
needed.
Our results may appear to be at variance with those of another
Danish study of 5731 one-year survivors of BC in adolescence and
adulthood reporting an increased risk of hospitalization for
conduction disorders (ICD-codes I44-I45) (RR = 1.17, 95% CI
0.79–1.73) and disturbances of heart rhythm (ICD-codes I47-I49)
(RR = 1.26, 95% CI 1.09–1.45) [23]. However, the patients in that
study were less than 40 years old at diagnosis compared with
our mean age of 57 years, no information was available on RT,
and the arrhythmias may not have been so severe as to indicate
a CIED. Other studies of BC are based on a much smaller number
of patients, 69 in the study of Strender et al. [15] and two in a case
report from 1977 [24].
Most studies observing arrhythmias and conduction abnormal-
ities after RT are based on HL patients treated with mantle field
irradiation [10–13], with typical mean heart doses around 20 Gy
[25]. All RT given to patients aged less than 70 years at BC diagno-
sis, has followed the DBCG guidelines of that particular time per-
iod. The heart doses from these techniques have been estimated
previously to be lower with mean heart doses around 1–5 Gy for
right-sided and 1–10 Gy for left-sided RT respectively [26–28].
Moreover, the SA and the AV nodes are located relatively far from
the radiation field for BC as illustrated in Fig. 2, while the mantle
field may cover the entire mediastinum. It is also difficult to
compare patients with BC and HL due to the different age distribu-
tions with a median age at diagnosis for HL being 38 years of age
compared with 61 years of age for BC (valid in 2012)[29].
Comparing left- versus right-sided RT can be used when mean
heart dose is considered the exposure variable of interest [26].
However, most PMs are implanted due to dysfunction of the SA
Table 2
Overview of implanted devices by indication by type of implant among 44,423 women with breast cancer, diagnosed in 1982–2005.
Implantation indication CRTa ICDb PMc Total
Sinus node dysfunction
Sinus node dysfunction with pause 1 117 118
Sinus node dysfunction without pause 24 24
Sinus node dysfunction unspecified 27 27
Bradycardia – Tachycardia syndrome 97 97
Atrioventricular block
AV block – 1 1 1
AV block – 2 type I 8 8
AV block – 2 type II 27 27
AV block – 2:1 6 6
AV block – 3 1 129 130
AV conduction impaired – status unknown 4 4
Left bundle branch block 11 3 14
Right bundle branch block 2 2
Bundle branch block, unspecified 1 6 7
Chronic atrial fibrillation & AV block 1 6 7
Tachyarrhythmia
Ventricular Fibrillation 1 10 11
VT – monomorphic Non-sustained 1 6 7
Wide complex tachycardia unspecified 1 1
Syncope with inducible VT or VF 1 1
Prophylactic (none documented) 5 5 10
Others
Chronic atrial fibrillation & bradycardia 59 59
Polymorphic VT/Torsades des pointes 1 1
Arrhythmia not documented 2 5 7
Unknown 2 1 8 11
Any 27 23 530 580
a Cardiac Resynchronization Therapy.
b Implantable Cardioverter Defibrillator.
c Pacemaker.
Fig. 2. Left-sided breast cancer radiotherapy CT-plan. Illustration of the dose
distribution form left-sided tangential radiotherapy. The mean heart dose is 8.4 Gy.
SN: Sinoatrial node. AV: Atrioventricular node.
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node and/or the AV node which are located in the right side of the
heart, and more or less placed in the midline of the mediastinum. It
was therefore not surprising that a risk estimate close to unity was
obtained comparing left- with right-sided RT in this study.
Larsen et al. [30] investigated ECG changes and arrhythmias
after cancer therapy in children and young adults. They included
134 patients with different types of malignancies (non-breast can-
cer) treated with RT. The authors found an increase in ventricular
and supra-ventricular premature complexes. These were transient,
and not found at later follow-ups. The authors, however, further-
more found an increase in prolonged QT interval among young
patients who received anthracyclines, RT or both. This prolonged
QT interval was not transient and could increase the risk of severe
conditions (ventricular tachycardia, Torsades des pointes ventricu-
lar tachycardia) even for normally quite harmless ventricular pre-
mature complexes. It has been suggested that radiation induced
fibrosis in the heart is associated with increases in ventricular ecto-
pic activity [12]. In healthy hearts, ectopic activity occurrence is
usually associated with no clinical significance, but can be a life
threatening condition, if the patient is known to have other cardiac
diseases [31]. Among patients at high-risk for ventricular tachycar-
dia, this is an indication for implantation of an ICD.
We found an increased risk of CIED among patients with cardiac
disease prior to BC. This was expected, as preexisting cardiac dis-
ease is a strong risk factor for having another (more severe) cardiac
disease, as well as developing cardiac conduction abnormalities,
i.e. the reason for having a CIED implant. Previous studies have
shown that RT increases the risk of ischemic heart disease[5], pos-
sibly by acceleration of coronary arteriosclerosis [32,33]. However,
it was surprising that the multivariate analysis showed a signifi-
cant association between CIED implantation and axillary lymph
nodal status and estrogen receptor status. We have no obvious
explanation for this finding other than possibly residual confound-
ing by factors which were not included in the present analysis.
A strength of the present study is that it is based on an entire
population of women treated for BC in Denmark between 1982
and 2005. Follow-up was complete through register-data provided
by the DBCG and the DPIR. All patients had valid information on RT
Table 3
Observed and expected numbers of CIED with corresponding univariate (crude) and multivariate standardized incidence ratios (SIR) among breast cancer patients in Denmark
diagnosed in 1982–2005.
Numbers of CIEDa Univariateb Multivariatec
Observed Expected SIRd 95% CI IRRe 95% CI p IRR 95% CI p
All 580 573.2 1.01 (0.93–1.10)
Radiotherapy 0.37 0.22
Yes 179 170.4 1.05 (0.91–1.22) 1.09 (0.91-1.30) 1.13 (0.93–1.38)
No 401 402.7 1.00 (0.90–1.10) 1 1
Years since breast cancer diagnosisf 0.02 0.06
0–4 105 118.9 0.88 (0.73–1.07) 1 1
5–9 143 161.7 0.88 (0.75–1.04) 1.00 (0.78–1.29) 1.02 (0.79-1.31)
10–14 158 133.6 1.18 (1.01–1.38) 1.34 (1.05–1.71) 1.28 (0.98–1.66)
15–19 99 88.2 1.12 (0.92–1.37) 1.27 (0.97–1.67) 1.15 (0.85–1.56)
20–24 60 49.9 1.20 (0.93–1.55) 1.36 (0.99–1.87) 1.09 (0.76–1.58)
25+ 15 20.9 0.72 (0.43–1.19) 0.81 (0.47–1.40) 0.61 (0.34–1.10)
Age at breast cancer diagnosis (yrs) 0.75 0.78
<50 58 52.4 1.11 (0.86–1.43) 1 1
50–59 133 126.4 1.05 (0.89–1.25) 0.94 (0.69–1.29) 0.94 (0.68–1.30)
60–69 241 230.0 1.05 (0.92–1.19) 0.95 (0.70–1.28) 0.89 (0.65–1.22)
70–79 148 164.4 0.90 (0.77–1.06) 0.86 (0.62–1.19) 0.83 (0.57–1.21)
Axillary lymph node status 0.29 0.01
Node positive 206 190.6 1.08 (0.94–1.24) 1 1
Node negative 362 372.2 0.97 (0.88–1.08) 0.88 (0.74–1.05) 0.69 (0.53–0.90)
Unknown 12 10.3 1.16 (0.66–2.05) 1.13 (0.63–2.03) 1.13 (0.61–2.12)
Estrogen receptor status <0.01 0.04
Positive (P10%) 377 374.5 1.01 (0.91–1.11) 1 1
Negative (0–9%) 62 83.4 0.74 (0.59–0.95) 0.73 (0.56–0.96) 0.73 (0.55–0.97)
Unknown 141 115.3 1.22 (1.04–1.44) 1.19 (0.97–1.46) 1.07 (0.86–1.34)
Laterality of breast cancer 0.92 0.96
Left 301 298.6 1.01 (0.90–1.13) 1 1
Right 279 274.6 1.02 (0.90–1.14) 1.01 (0.86–1.19) 1.00 (0.85–1.18)
Adjuvant medical treatment 0.78 0.11
Anthracyclines 14 16.2 0.86 (0.51–1.46) 0.84 (0.49–1.45) 0.83 (0.46–1.51)
Other chemotherapy 43 44.6 0.96 (0.71–1.30) 0.89 (0.65–1.23) 0.68 (0.46–1.00)
Endocrine therapy (alone) 153 155.6 0.98 (0.84–1.15) 0.94 (0.77–1.16) 0.71 (0.53-0.95)
None 296 272.5 1.09 (0.97–1.21) 1 1
Unknown/Indicated. but not reported 74 84.2 0.88 (0.70–1.10) 0.86 (0.66–1.12) 0.74 (0.53–1.02)
Prior cardiac diseaseg <0.01 <0.01
Conduction disorders & arrhythmiash 43 12.5 3.43 (2.54–4.63) 4.27 (3.11–5.86) 4.85 (3.51–6.68)
Other cardiac diseasesi 69 37.2 1.86 (1.47–2.35) 2.27 (1.76–2.94) 2.51 (1.94–3.26)
No/Unknown 468 523.5 0.89 (0.82–0.99) 1 1
a Cardiovascular Implantable Electronic Devices.
b Adjusted for time at risk (started 6 month after breast cancer diagnosis).
c Adjusted for year of breast cancer diagnosis, time at risk (started 6 month after breast cancer diagnosis), age at breast cancer diagnosis, axillary lymph node status,
estrogen receptor status, laterality of breast cancer, adjuvant medical treatment and prior cardiac disease.
d Standardize incidence ratio.
e Incidence rate ratio.
f Time at risk started 6 month after breast cancer diagnosis.
g Defined as having any of the following ICD-codes at least 30 days before cancer diagnosis.
h ICD10 I44, I45, I47–49 & ICD8 427.90–427.98.
i ICD10 I00-I52 & ICD8 390.00–429.99 (ICD-codes for conduction abnormality/arrhythmia not included).
64 Risk of pacemaker after radiotherapy for breast cancer
since patients with unknown RT status were excluded. In this
study we used information from the general female population
on rates of CIED implants. This information was ascertained inde-
pendently of RT status, and only first-time implants were included.
However, there are limitations too. In some situations, compar-
isons of BC patients who received RT with BC patients who did not
can be biased, because BC patients selected for RT may have a
lower baseline risk of cardiovascular disease than BC patients
who did not receive RT [34]. Our study population may have had
a lower baseline risk for cardiac disease compared to the back-
ground population due to higher socioeconomic status, resulting
in a selection bias [35,36]. This could mask a real increased risk
for CIED implants after RT, i.e. our estimates could be underesti-
mated. In addition, we do not have any information on known risk
factors for the development of heart disease, such as smoking sta-
tus, diabetes, obesity or cholesterol status.
There is a possibility of surveillance bias when SIRs are used,
since BC patients are followed more closely in the healthcare sys-
tem compared to the general population. However, if a patient suf-
fers from cardiac disease which indicates a CIED, anyone in the
general population would have been identified, especially as the
healthcare services in Denmark are free of charge. Finally, we
excluded about 31% (10,894 women) of potentially eligible
patients with no certain information on RT status in the DBCG
database. Unfortunately, this was the price for obtaining a high
degree of certainty in the estimates of the effect of RT.
Conclusion
Adjuvant RT as practiced in Denmark for early stage BC did not
increase the risk of so severe ventricular arrhythmias or cardiac
conduction abnormalities in the heart that CIEDs were needed.
This is reassuring for women receiving RT for BC.
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